IL22 and metabolic dysfunction-associated steatohepatitis: Given its pleiotropic functions, including anti-steatotic, anti-inflammatory, and anti-fibrotic effects within the liver, IL-22 is a promising candidate for treating MASLD/MASH (Huang et al., 2025).